Castle Biosciences' Melanoma Test Refines Risk Stratification Beyond Staging
Event summary
- Castle Biosciences will present data at AAD 2026 showing DecisionDx-Melanoma significantly improves mortality risk prediction within AJCC stages for cutaneous melanoma patients.
- Study of 1,868 SEER-linked patients found five-year melanoma-specific survival varied widely within the same stage based on test results.
- For T1 tumors, five-year survival was 96.7% for low-risk vs. 70.0% for high-risk test results; for Stage IIB–III, it was 87.4% vs. 48.5%.
- Test identifies high-risk thin (T1) melanomas with mortality risk approaching thicker tumors and lower-risk patients suitable for less intensive follow-up.
The big picture
Castle Biosciences' data challenges the sufficiency of traditional AJCC staging for melanoma risk assessment, aligning with broader trends toward molecular diagnostics that refine treatment pathways. The findings could support more precise, cost-effective care by tailoring interventions to individual patient risk profiles, a growing priority in oncology.
What we're watching
- Clinical Adoption
- Whether dermatologists and oncologists will integrate DecisionDx-Melanoma into routine risk assessment to guide personalized treatment decisions.
- Regulatory Impact
- How these findings may influence reimbursement policies or clinical guidelines for melanoma management.
- Competitive Positioning
- The pace at which Castle Biosciences can differentiate its test in a market increasingly focused on precision oncology tools.
Our editorial coverage:
Related topics